Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2021-10-11 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
关于公司HA树脂血液灌流器被列入《血液灌流在维持性血液透析患者中的临床应用上海专家共识》的自愿性信息披露公告
Regulatory Filings Classification · 95% confidence The document is a voluntary information disclosure announcement by the company regarding the inclusion of its HA resin blood perfusion device in a clinical expert consensus published by a medical society. It discusses clinical application guidance, treatment recommendations, and potential impact on the company. There are no financial statements, regulatory filings, or report publications mentioned. The document is an announcement of clinical and product-related information rather than a financial or regulatory report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a voluntary disclosure announcement about product clinical recognition and its potential impact on the company, which aligns best with Regulatory Filings (RNS) as a fallback category for miscellaneous announcements that do not fit other specific categories.
2021-10-11 Chinese
关于公司董事会秘书辞职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of the company's board secretary. It details the resignation date, the outgoing secretary's shareholding, and the interim arrangement for the role. There is no financial data, no report attached or referenced as being published, and no mention of financial results or regulatory certifications. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2021-09-30 Chinese
独立董事关于第四届董事会第二十六次会议相关事项的独立意见
Board/Management Information Classification · 90% confidence The document is an independent opinion from independent directors regarding a specific board meeting matter related to the use of funds and compliance with regulations. It references company laws, securities laws, and internal company rules, and it is a formal statement of opinion rather than a full report or announcement of voting results. The document length is short (583 characters), and it does not contain financial statements or detailed financial data. It is not a report publication announcement or a certification letter but a management-related opinion on board matters. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or opinions related to board or senior management activities.
2021-09-28 Chinese
关于使用基本户及一般户支付募投项目人员费用并以募集资金等额置换的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from a company regarding the use of funds raised through convertible bonds for specific investment projects. It details the approval process by the board and supervisory committee, independent director opinions, and the involvement of the sponsoring institution. The document focuses on the operational and procedural aspects of using raised funds, specifically the use of basic and general accounts to pay personnel expenses related to the investment projects and the subsequent reimbursement from the raised funds. It does not contain financial statements, earnings data, or detailed financial performance analysis. It is not a full annual or interim report, nor is it a call transcript or legal proceeding. It is a regulatory announcement about the use of capital raised and the related approvals and opinions. Given the content and length (3627 characters), it is not a report publication announcement but a regulatory filing. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2021-09-28 Chinese
中航证券有限公司关于公司使用基本户及一般户支付募投项目人员费用并以募集资金等额置换的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from a sponsoring institution (中航证券有限公司) regarding the use of basic and general accounts to pay personnel expenses for projects funded by raised capital by 健帆生物科技集团股份有限公司. It references regulatory guidelines, approval by the board and supervisory committee, independent directors' opinions, and compliance with fundraising management rules. The document includes detailed descriptions of the fundraising, project investment, and the operational process for fund usage. It is not a financial report like an annual or interim report, nor is it a brief announcement or a certification letter. It is a regulatory compliance and verification report related to the use of raised funds, which fits best under Regulatory Filings (RNS) as it does not fit other specific categories such as Capital/Financing Update or Audit Report. The document length is 3416 characters, which is relatively short but contains substantive content rather than just an announcement or certification. Therefore, the best classification is Regulatory Filings (RNS).
2021-09-28 Chinese
第四届董事会第二十六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 26th meeting of the 4th Board of Directors of the company. It details the meeting attendance, the agenda discussed, and the voting results. It references a related announcement published on the regulatory disclosure website but does not contain detailed financial data or a full report. The content is focused on board decisions and meeting outcomes, which aligns with Board/Management Information filings. The document length is short and it is an announcement rather than a full report or detailed presentation.
2021-09-28 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.